Pharmaceutical innovation

Handbook of the Economics of Innovation

Volumn 1, Issue 1 C, 2010, Pages 539-574

  Scherer, F M ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Innovation; Parallel paths; Pharmaceuticals; Product quality regulation; Profitability; Research and development; Virtuous rent seeking

Indexed keywords

EID: 84872400785     PISSN: 22108807     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0169-7218(10)01012-9     Document Type: Chapter

References (86)

1. Adams, J.D., Clemmons, J.R. (2008). "Industrial scientific discovery". National Bureau of Economic Research Working Paper No. 13823.
2. Angell, M. (2004). The Truth About the Drug Companies. New York, Random House.
3. Azoulay, P. (2003). "Acquiring knowledge within and across firm boundaries: Evidence from clinical development". National Bureau of Economic Research Working Paper 10083.
4. Barzel, Y. (1968). "Optimal timing of innovations". Review of Economics and Statistics 50, 348-355.
5. Berndt, E., Hurvitz, J. (2005). "Vaccine advance-purchase agreements for low-income countries". Health Affairs 24, 653-665.
6. Berndt, E., Cockburn, I., Thiers, F. (2007). "The globalization of clinical trials for new medicines into emerging economies". Paper presented at a UNU-MERIT conference, Maastricht, Netherlands.
7. Bond, R.S., Lean, D. (1977). Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets. Federal Trade Commission staff report, Washington.
8. Branscomb, L., Auerswald, P. (2001). Taking Technical Risks. MIT Press, Cambridge, MA.
9. Carr, G. (1998). "The pharmaceutical industry". The Economist 21, 1-18, special survey (February).
10. Clymer, H.M. (1970). "The changing costs of pharmaceutical innovation". In: Cooper, J. (Ed.), The Economics of Drug Innovation. American University Center for the Study of Private Enterprise, Washington, pp. 109-124.
11. Cockburn, I.M. (2006). "Is the pharmaceutical industry in a productivity crisis?" Innovation Policy and the Economy 7, 1-32.
12. Cockburn, I.M., Henderson, R. (1994). "Racing to invest? The dynamics of competition in ethical drug discovery". Journal of Economics and Management Strategy 3, 481-519.
13. Cockburn, I.M., Henderson, R. (1998). "Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery". Journal of Industrial Economics 46, 157-182.
14. Cockburn, I.M., Henderson, R. (2000). "Publicly funded science and the productivity of the pharmaceutical industry". Innovation Policy and the Economy 1, 1-34.
15. Cockburn, I.M., Henderson, R., Stern, S. (1999). "The diffusion of science driven drug discovery". National Bureau of Economic Research Working Paper 7359.
16. DiMasi, J.A. (2000). "New drug innovation and pharmaceutical industry structure: Trends in the output of pharmaceutical firms". Drug Information Journal 34, 1169-1194.
17. DiMasi, J.A., Paquette, C. (2004). "The economics of follow-on drug research and development". PharmacoEconomics 22, 1-14.
18. DiMasi, J.A., Hansen, R., Grabowski, H., Lasagna, L. (1991). "Cost of innovation in the pharmaceutical industry". Journal of Health Economics 10, 107-142.
19. DiMasi, J.A., Hansen, R., Grabowski, H., Lasagna, L. (1995). "Research and development costs for new drugs by therapeutic category". PharmacoEconomics 7, 152-169.
20. DiMasi, J.A., Hansen, R., Grabowski, H. (2003). "The price of innovation: New estimates of drug development costs". Journal of Health Economics 22, 151-185.
21. Dorfman, R., Steiner, P.O. (1954). "Optimal advertising and optimal quality". American Economic Review 44, 826-836.
22. Gambardella, A. (1995). Science and Innovation: The US Pharmaceutical Industry During the 1980s. Cambridge University Press, Cambridge, UK.
23. Grabowski, H., Vernon, J.M. (1990). "A new look at the returns and risks to pharmaceutical R&D". Management Science 36, 804-821.
24. Grabowski, H., Vernon, J.M. (1994). "Returns on new drug introductions in the 1980s". Journal of Health Economics 13, 383-406.
25. Grabowski, H., Vernon, J.M., Thomas, L.G. (1978). "Estimating the effects of regulation on innovation: An international comparative analysis". Journal of Law and Economics 21, 133-163.
26. Grabowski, H., Vernon, J.M., DiMasi, J. (2002). "Returns on research and development for 1990s new drug introductions". PharmacoEconomics 20 (SUPPL. 3), 16-27.
27. Groopman, J. (2008). "Superbugs". The New Yorker 46-55 (August 11, 2008).
28. Harbridge House, Inc.. (1967). Patent Policy Study: Task IV, Drug Study. Harbridge House, Inc., Boston
29. Harhoff, D., Scherer, F.M. (2000). "Technology policy for a world of skew-distributed outcomes". Research Policy 29, 559-566.
30. Healy, E.M., Kaitin, K. (1999). "The European Agency for the Evaluation of Medicinal Products' centralized procedure for product approval: Current status". Drug Information Journal 33, 969-978.
31. IIT Research Institute. (1968). Technology in Retrospect and Critical Events in Science. National Science Foundation, Washington, DC.
32. Institute of Medicine, National Academies of Science. (2006). The Future of Drug Safety. National Academies of Science, Washington, DC.
33. Kettler, H.E. (2000). "Pharmaceutical and biotechnology industries coalescing". Presentation at the American Enterprise Institute, Washington, DC.
34. Kingston, W. (2000). "Antibiotics, invention, and innovation". Research Policy 29, 679-710.
35. Kitch, E.W. (1973). "The patent system and the new drug application". In: Landau, R.L. (Ed.), Regulating New Drugs. University of Chicago Center for Policy Study, Chicago, pp. 81-108.
36. Krueger, A.O. (1974). "The political economy of the rent-seeking society". American Economic Review 64, 291-303.
37. Lanjouw, J.O. (1999). "The introduction of pharmaceutical product patents in India". National Bureau of Economic Research working paper no. 6366.
38. Lanjouw, J.O. (2002). "Intellectual property and the availability of pharmaceuticals in poor countries". Center for Global Development working paper no. 5, Washington, DC.
39. Levin, R.C., Klevorick, A.K., Nelson, R.R., Winter, S. (1987). "Appropriating the returns from industrial research and development". Brookings Papers on Economic Activity 1987 (3), 783-820.
40. Levine, R., Kremer, M., Albright, A. (2005). Making Markets for Vaccines: Ideas to Action. Center for Global Development, Washington, DC.
41. Lichtenberg, F.R. (2001). "The benefits and costs of newer drugs: Evidence from the 1996 medical expenditure panel survey". National Bureau of Economic Research working paper 8147.
42. Lichtenberg, F.R. (2004). "Public policy and innovation in the U.S. pharmaceutical industry". In: Holtz-Eakin, D., Rosen, H. (Eds.), Entrepreneurship and Public Policy. MIT Press, Cambridge, MA.
43. Lichtenberg, F.R. (2007). "The impact of new drug launches on U.S. longevity and medical expenditure". American Economic Review 97 (Suppl.), 438-441.
44. Long, G., et al. (2006). "The impact of hypertension drugs on the number and risk of deaths, strokes, and myocardial infarctions". National Bureau of Economic Research working paper 12096.
45. Love, J. (2003). Evidence regarding research and development investment in innovative and non-innovative medicines. Consumer Project on Technology (CPTECH), Washington, DC.
46. Mann, C.C., Plummer, M.L. (1991). The Aspirin Wars. Harvard Business School Press, Boston.
47. Mansfield, E. (1970). "Discussion". In: Cooper, J. (Ed.), The Economics of Drug Innovation. American University, Washington, DC, pp. 149-154.
48. Mansfield, E. (1977). "Social and private rates of return from industrial innovations". Quarterly Journal of Economics 91, 221-240.
49. Mansfield, E. (1986). "Patents and innovation: An empirical study". Management Science 32, 173-181.
50. Mansfield, E. (1998). "Academic research and industrial innovation: An update of empirical findings". Research Policy 26, 773-776.
51. Maxwell, R.A., Eckhardt, S.B. (1990). Drug discovery: A case book and analysis. Humana Press, Clifton NJ.
52. McFetridge, D.G., Rafiquzzaman, M. (1986). "The scope and duration of the patent right and the nature of research rivalry". Research in Law and Economics 8, 91-129.
53. Medicins Sans Frontieres Access to Essential Medicines Campaign. (2001). Fatal Imbalance: The Crisis in Research and Development for Neglected Diseases. Medicins Sans Frontieres, Geneva, Switzerland.
54. Murphy, K.M., Topel, R.H. (2006). "The value of health and longevity". Journal of Political Economy 114, 871-904.
55. Nordhaus, W.D. (1969). Innovation, Growth, and Welfare. MIT Press, Cambridge, MA.
56. Peck, M.J., Scherer, F.M. (1962). The Weapons Acquisition Process: An Economic Analysis. Harvard Business School Division of Research, Boston, MA.
57. Pharmaceutical Research and Manufacturers of America. (2006). Pharmaceutical Industry Profile: 2006. Pharmaceutical Research and Manufacturers of America, Washington, DC.
58. Pisano, G.P. (2006). Science Business: The Promise, the Reality, and the Future of Biotech. Harvard Business School Press, Boston, MA.
59. Powell, W.N., Grodal, S. (2005). "Networks and innovators". In: Fagerberg, J., Mowery, D.C., Nelson, R. (Eds.), Oxford Handbook of Innovation. Oxford University Press, Oxford, pp. 56-85.
60. Reichert, J.M., Milne, C.P. (2002). Public and private sector contributions to the discovery and development of 'impact' drugs. Tufts University Center for the Study of Drug Development White Paper, Boston, MA.
61. Robinson, W.T., Fornell, C. (1985). "Sources of market pioneer advantages in consumer goods industries". Journal of Marketing Research 22, 305-317.
62. Scherer, F.M. (1966). "Time-cost tradeoffs in uncertain empirical research projects". Naval Research Logistics Quarterly 12, 71-82.
63. Scherer, F.M. (1967). "Research and development resource allocation under rivalry". Quarterly Journal of Economics 81, 359-394.
64. Scherer, F.M. (1996). Industry Structure, Strategy, and Public Policy. HarperCollins, New York.
65. Scherer, F.M. (2001a). "The link between gross profitability and pharmaceutical R&D spending". Health Affairs 20, 216-220.
66. Scherer, F.M. (2001b). "The innovation lottery". In: Dreyfuss,, R.et al. (Ed.), Expanding the Boundaries of Intellectual Property. Oxford University Press, Oxford, pp. 3-21.
67. Scherer, F.M. (2004). "A note on global welfare in pharmaceutical patenting". The World Economy 27, 1127-1142.
68. Scherer, F.M. (2007a). "Schumpeter and the micro-foundations of endogenous growth". In: Hanusch, H., Pyka, A. (Eds.), The Elgar Companion to Neo-Schumpeterian Economics. Edward Elgar, Cheltenham, UK, pp. 671-687.
69. Scherer, F.M. (2007b). Parallel Paths Revisited. John F. Kennedy School of Government, Harvard University, Cambridge, MA. Working Paper RWP07-040.
70. Scherer, F.M. (2009). "The political economy of patent policy reform in the United States". Journal on Telecommunications and High Technology Law 7, 167-216.
71. Schwartzman, D. (1976). Innovation and the Pharmaceutical Industry. Johns Hopkins University Press, Baltimore.
72. Schwartzman, D. (1996). "Has pharmaceutical research become more scientific?" Review of Industrial Organization 11, 841-851.
73. Shulman, S., Mannocchia, M. (1997). "The US orphan drug programme: 1983-1995". PharmacoEconomics 9, 312-326.
74. Simons, J. (2003). "The $10 billion pill". Fortune 20, 58-68 (January).
75. Stauffer, T.R. (1971). "The measurement of corporate rates of return: A generalized formulation". Bell Journal of Economics and Management Science 2, 434-469.
76. Stigler, G.J. (1968). "Price and non-price competition". Journal of Political Economy 72, 149-154.
77. Tufts Center for the Study of Drug Development. (2006). Impact Report. Tufts Center for the Study of Drug Development, Boston, MA, vol. 8, no. 3, pp. 1-4.
78. Tullock, G. (1967). "The welfare costs of tariffs, monopolies and theft". Western Economic Journal 5, 224-232.
79. U.S. Federal Trade Commission. (1958). Economic Report on Antibiotics Manufacture. U.S. Federal Trade Commission, Washington, DC.
80. U.S. Federal Trade Commission. (1985). Statistical Report: Annual Line of Business Report: 1977. U.S. Federal Trade Commission, Washington, DC.
81. U.S. Food and Drug Administration, Pilot Drug Evaluation Staff. (1993). "The 007 experiment-An approach to change". unpublished internal assessment, Rockville, MD.
82. U.S. Office of Technology Assessment. (1993). Pharmaceutical R&D: Costs, Risks, and Rewards. U.S. Office of Technology Assessment, Washington, DC.
83. Vernon, J.A., Hughen, W.K. (2005). "The future of drug development: The economics of pharmagenomics". National Bureau of Economic Research Working Paper 11875.
84. Ward, M.R., Dranove, D. (1995). "The vertical chain of research and development in the pharmaceutical industry". Economic Inquiry 33, 70-87.
85. Werth, B. (1994). The Billion Dollar Molecule. Simon & Schuster, New York.
86. Zucker, L., Darby, M., Armstrong, J. (1998). "Geographically localized knowledge: Spillovers or markets?" Economic Inquiry 36, 65-86.